Abstract:Background: The role of nipple-sparing mastectomy for breast cancer is controversial, as there is concern regarding its oncologic safety and complication rate. The authors reviewed the literature to quantify the incidence of occult nipple malignancy in breast cancer, identify the factors influencing occult nipple malignancy, quantify locoregional recurrence rates, and quantify nipple-sparing mastectomy complication rates. Methods: A search of the literature was performed using PubMed. Key words used were “mastectomy,” “nipple involvement,” “nipple-sparing mastectomy,” “skin-sparing mastectomy,” “occult nipple malignancy,” “occult nipple disease,” and “breast cancer recurrence.” Articles were analyzed regarding incidence of occult nipple malignancy, potential factors influencing the incidence of occult malignancy, and recurrence/complications following nipple-sparing mastectomy. The incidence of occult nipple disease was compared between groups using chi-square or Fisher’s exact tests for categorical variables and t tests for continuous variables. Values of p < 0.05 were considered significant. Results: The overall rate of occult nipple malignancy was 11.5 percent. Primary tumor characteristics influencing occult nipple malignancy were tumor-nipple distance less than 2 cm, grade, lymph node metastasis, lymphovascular invasion, human epidermal growth factor receptor-2–positive, estrogen receptor/progesterone receptor–negative, tumor size greater than 5 cm, retroareolar/central location, and multicentric tumors. The overall nipple recurrence rate considered significant was 0.9 percent, and the skin flap recurrence rate was 4.2 percent. Full- and partial-thickness nipple necrosis rates were 2.9 and 6.3 percent, respectively. Conclusions: Nipple-sparing mastectomy for primary breast cancer is appropriate in carefully selected patients. All patients should have retroareolar sampling. There is strong evidence to suggest that suitable cases are well circumscribed single or multifocal lesions that have a tumor-to-nipple distance greater than 2 cm. Tumors should be grade 1 to 2 and not have lymphovascular invasion, axillary node metastasis, or human epidermal growth factor receptor-2 positivity.

Canavan Disease: Studies on the Knockout Mouse

Canavan disease: Clinical features and recent advances in research

The pathogenesis of, and pharmacological treatment for, Canavan disease

Images in clinical medicine. Ischemic gangrene.

Loss of Central Auditory Processing in a Mouse Model of Canavan Disease

Astroglial conditional Slc13a3 knockout is therapeutic in murine Canavan leukodystrophy

A new mouse model of Canavan leukodystrophy displays hearing impairment due to central nervous system dysmyelination

[Hypodense nodular images in the spleen of a patient with human immunodeficiency virus infection].

Brain N-acetylaspartate accumulation in Canavan disease is not neurotoxic per se: the implications of the first gene replacement therapy study to demonstrate successful post-symptomatic treatment in mice

Cellular and molecular mechanisms of aspartoacylase and its role in Canavan disease

Dual-function AAV gene therapy reverses late-stage Canavan disease pathology in mice

Metastatic Renal Cell Carcinoma to the Contralateral Ureter: A Rare Phenomenon

Canavan Disease - A Rare Case Report

Two patients with Canavan disease and structural modeling of a novel mutation

The effect of ordering of internal water in thaumatin and lysozyme crystals as revealed by Raman method

Therapeutic development for Canavan disease using patient iPSCs introduced with the wild-type ASPA gene

Maternal lung growth in surgically reduced litter size pregnancy.

[A retrospective evaluation of exposure to dichloromethane by using a job-exposure matrix].

Clinically Distinct Phenotypes of Canavan Disease Correlate with Residual Aspartoacylase Enzyme Activity

The Role of Nipple-Sparing Mastectomy in Breast Cancer: A Comprehensive Review of the Literature

Cell‐Based Therapy for Canavan Disease Using Human iPSC‐Derived NPCs and OPCs